US Ambassador to Egypt Herro Mustafa Garg joined His Excellency Prime Minister Dr. Mostafa Madbouly, Minister of Investment and Foreign Trade Engineer Hassan Al-Khatib, and Minister of Planning, Economic Development, and International Cooperation Dr. Rania Al-Mashat, at a signing ceremony between American company Dawah Pharmaceuticals and Egyptian company Gypto Pharma. The agreement between Dawah Pharmaceuticals, a leader in critical therapies, and Gypto Pharma, a regional pharmaceutical hub, will establish new pharmaceutical manufacturing facilities in Egypt, utilizing cutting-edge American technology. This agreement demonstrates how American expertise can transform Egypt's pharmaceutical industry.
The agreement includes an initiative aimed at meeting Egyptian market demand and expanding export opportunities to key markets, including the United States, Europe, Africa, and the MENA region, benefiting both the Egyptian and U.S. economies. The agreement benefits both the United States and Egypt as it will increase American exports to Egypt and establish new pharmaceutical manufacturing facilities in Egypt.
In turn, Ambassador Mustafa Garg emphasized the significance of the agreement, stating, “The critical element of this landmark agreement between Dawah Pharmaceuticals and Gypto Pharma is the supply of state-of-the art U.S. machinery, equipment, and technologies along with the know-how and expertise to expand the reach of Egyptian pharmaceutical production throughout Africa and the Middle East. This partnership showcases the strength of our bilateral economic relationship and the shared prosperity it brings to both Egypt and the United States.”
The deal between Dawah Pharmaceuticals and Gypto Pharma is expected to create jobs and stimulate trade and investment in both Egypt and the United States with initial plans by Gypto to build a biosimilar manufacturing plant and a bioequivalence testing facility in New Jersey.
Follow the latest news on Google News
